Overview of therapeutic approaches in development for DMD May 29 2014
Dystrophin
Dystrophin
Annemieke Aartsma-Rus
Therapeutic approaches • Cell therapy • Genetic therapy • Exon skipping • Stop codon read through
Annemieke Aartsma-Rus
4 | TREAT-NMD Outcome Patient Care Joint EuroBioBank Standards Action & Website 2007-2011 Registries measures Trial research TACT SOPs Plan Site of & EU fundedRegistry Network Diagnosis Communication & Care
Three year work plan
www.treat-nmd.eu
Standardized genetic & Unique network of 18 Tests to decide whether TREAT-NMD Unified Regular experimental meetings 3 year Advisory plan to clinical2012 core data for trial members treatment being tested in onwards consolidate protocols Committee improve efforts and the for International consensus Information Extensive about website each recruitment a comparability trial is Alliance having any effect funded jointly Milestone-driven tackle Therapeutics, ofcommon studies publication recommended registered trial site kept in Stores & distributes problems approach through multiple 250,000 annualfor page hits standards of care Interface can vary one location ease of 440,000 Vital to quality use the DNA, correct cell Drawn Expert multidisciplinary up by a group of streams with global between countries whilst comparison outcome and tissue measure samples to 70,000 visitors annually Topics independent Maintains on researchers necessity, network body DMD-SMA-CMD-LGMD stillbased able to share core partners & membership prove if a in treatment works (listed momentum hosting each to & be protocol) establish rotated data Addresses organisational Monthly newsletter sent Independent between and new objective partners goals Family guides difficulties of identifying Governance Working harmonise the toto 3,500 recipients Ethical & governance best Approx guidance 40 sops on advancing updated in 25 different languages appropriate sites when Chair –of Annemieke Aartsmause most appropriate practice new therapies regularly for translations verified Rus setting up a trial Proven communication outcome measures for neuromuscular diseases Vice Chair – Ericplatform Hoffman >10,000 DMD diseases patients different Printed booklets or across countries Leads --30 Eric Hoffman Executive Committee Leads Marina Mora download from Lead Eugenio Mercuri Annemieke Aartsma-Rus Supported by academic Lucia Monaco Chair- Jan – Dominic Wells Secretariat - Verschuuren Katewebsite Bushby Leads Filippo Buccella
advisory boardVolker (“task force”) Marco Crimi Straub Coordinated Hugh by University Dawkins Funding - Telethon & Parent of NMD leaders Funding - US Sejersen (Dept of Leads - Thomas Medical Center Freiburg Organizations Funding COST Funding -Kathy Fondazione Funding – EC Defense) Funding -(operating AFM North & EC Telethon grant) (operating grant)
Cell therapy
Muscle stem cells • Isolate muscle stem cells from healthy donor • Expand outside the body (culture in lab) • Transplant into patients • Transplanted cells repair muscle • Transplanted cells make dystrophin Annemieke Aartsma-Rus
Muscle stem cells (myoblasts) • Immune response (suppress) • Do not exit circulation after injection • Local injection: stay close to injection site • Tremblay (Canada): multiple local injections • Local dystrophin restoration • Not feasible for larger muscles
Annemieke Aartsma-Rus
Stem cell therapy Stem cells from fat, bone and bloodvessel walls • Can exit bloodstream and migrate into muscle • Very low efficiency Mesangioblasts most promising • Encouraging results in dog model • Safety trial ongoing in Italy (Giulio Cossu) • 3 patients received stem cells • Some side effects • Preparing for injection 2 more patients Annemieke Aartsma-Rus
Niche Muscle damage
Repair
Inflammation
Fibrosis • Dystrophic muscle is damaged (scar tissue/fibrosis) • The few transplanted stem cells that reach muscle • Do not receive proper signals to become muscle • Receive signals from scar tissue: more fibrosis Annemieke Aartsma-Rus
Cell therapy summary • Opportunities • Applicable to all patients • Deliver dystrophin gene and repair muscle • Currently in very early stage clinical development • Challenges • Efficiency very low • Damaged muscle gives wrong signals to cells • Immunity (only with allogenic transplantation) Annemieke Aartsma-Rus
Exon skipping Normal
Annemieke Aartsma-Rus
Duchenne
Dystrophin gene
Annemieke Aartsma-Rus
Duchenne: genetic code disrupted
Annemieke Aartsma-Rus
Duchenne: genetic code disrupted Exon 46
Exon 47
?
Exon 51
Exon 52
Protein translation stops prematurely
Dystrophin not functional Annemieke Aartsma-Rus
Becker: genetic code maintained Exon 46
Exon 47
Exon 52
Exon 53
Protein translation continues
Dystrophin partly functional Less damage Annemieke Aartsma-Rus
Exon skipping: restore genetic code
Annemieke Aartsma-Rus
Applicability
hotspot
Annemieke Aartsma-Rus
Aartsma-Rus Hum Mutat 2009, 30:293-9
Exon skip chemistries • Two chemistries in clinical development • GSK/Prosensa: 2’-O-methyl phosphorothioate (drisapirsen) • AVI-Biopharma/Sarepta: phosphorodiamidate morpholino oligomers (eteplirsen) • Exon 51
Annemieke Aartsma-Rus
Systemic study Sarepta II AVI-4658 (30 and 50 mg/kg) • Intravenous delivery • Earlier trial:20 mg/kg (12 weeks) is not sufficient • Weekly 12 weeks 50 mg/kg: biopsy • Weekly 24 weeks 30 mg/kg: biopsy • Weekly placebo 12 or 24 weeks: biopsy • After 24 weeks treatment: all 30 or 50 mg/kg/week • Patients have been treated for >90 weeks now Annemieke Aartsma-Rus
Dystrophin staining
Annemieke AartsmaRus
Department of Human Genetics
Annemieke Aartsma-Rus
19
Dystrophin results
Annemieke AartsmaRus
Department of Human Genetics
Annemieke Aartsma-Rus
20
Eteplirsen summary • Dystrophin restored for all patients 24 weeks after treatment • 6 minute walk test stabilized in 10/12 treated patients • No real placebo group • Sarepta plans confirmatory study for 2014 • Also preclinical work ongoing for exon 50, 45, 53 and 44 Annemieke Aartsma-Rus
Systemic trial (GSK/Prosensa) • Subcutaneous treatment for 5 weeks • 0.5, 1, 2 & 6 mg/kg • Dystrophin restored in 10/12 patients • 60-100% fibers dystrophin positive • Dystrophin levels up to 15.6% • Dose dependent increase in dystrophin levels
Annemieke Aartsma-Rus
Systemic trial (GSK/Prosensa) • All patients then enrolled in an open label extension study • 6 mg/kg drisapirsen per week for 72 weeks • Then 8 weeks break • Then cycles of 8 weekly doses, 4 week break • All patients still in trial • Treated now for almost 4 years
Annemieke Aartsma-Rus
Goemans et al, NEJM 2011, 364: 1513-22
PRO051-02 / DMD114673 Distance walked (m)
Efficacy
intermittent
Annemieke AartsmaRus
Weeks in extension study
24
Open Label Extenion Trial Drisapersen • Side effects observed • Local injection site reactions • Proteinuria (reversible during breaks) • Thrombocytopenia seen for some patients • Seen in all phase 2/3 trials drisapersen • 6 minute walk distance maintained for >3.5 years in 8/10 ambulant patients • Very encouraging results but no placebo group Annemieke Aartsma-Rus
Placebo-controlled trial drisapersen • 54 patients • Early stage of disease • Steroid treated • Treatment for 48 weeks with 6 mg/kg drisapersen subcutaneous or placebo • Weekly injections (18 patients) • Intermittent regimen (17 patients) • Placebo (18 patients) Annemieke Aartsma-Rus
Primary Endpoint: Change from Baseline (95% CI) in 6MWD (m), ITT Population
Visit
Comparison
Week 25 (Primary)
Week 49 (Secondary)
Treatment Difference
P-value
Weekly vs Placebo
35.09
0.014
Intermittent vs Placebo
3.51
0.801
Weekly vs Placebo
35.84
0.051
Intermittent vs Placebo
27.08
0.147
Drisapersen preliminary further analysis
Annemieke Aartsma-Rus
Placebo-controlled trial drisapersen • 51 patients • Early stage of disease (rise from floor <15 seconds) • Steroid treated • Treatment for 24 weeks with 3 or 6 mg/kg drisapersen subcutaneous or placebo • 24 week wash out Increased 6 minute walk distance for patients treated with 6 mg/kg vs placebo and 3 mg/kg Annemieke Aartsma-Rus
Study Design large placebo controlled trial
n = planned number randomized Numbers randomized (ITT and safety population) 6 mg/kg/week = 125 Placebo = 61
Primary Endpoint: 6MWD Adjusted Mean Change from Baseline (95% CI) in 6MWD (m) â&#x20AC;&#x201C; Primary MMRM analysis ITT Population
Treatment difference = 10.3m, p-value = 0.415 at Week 48
- 42.3 m 4.7m
4.8m
1.8m
- 52.7 m Curves offset for visualization
Drisapersen most recent news • GSK stops drisapersen development • Prosensa obtained all rights and data
• Further analysis done • Phase 3 population more advanced disease • For many patients 96 week information available Annemieke Aartsma-Rus
Drisapersen preliminary further analysis
Annemieke Aartsma-Rus
Drisapersen preliminary further analysis
Annemieke Aartsma-Rus
Other trials Prosensa/GSK Drisapersen •Redosing patients anticipated to start Q3 2014 •Discussion with regulators ongoing
Exon 44: •Study completed, extension anticipated Q3/4 2014
Exon 45 and Exon 53: •Dose finding studies ongoing •Anticipate 2nd phase 2015
Preclinical work: •Exon 55 & exon 52 and rare mutations Annemieke Aartsma-Rus
Stop codon readthrough
1
79
Annemieke Aartsma-Rus
PTC124/ataluren PTC
1
79 Cell ignores new stop signal Complete protein is made
Annemieke Aartsma-Rus
Stop codon readthrough summary • Opportunities • Oral delivery • Applicable to multiple diseases • Challenges • Mutation specific approach (15%)
Annemieke Aartsma-Rus
PTC124/Ataluren • Tested in healthy controls: safe • Tested in 28 patients (dose finding) • Safe • Increased dystrophin expression
• Tested in 174 patients in 48 week trial • Placebo, high dose and low dose • Safe! • No significant different in primary outcome (6MWT) • Dystrophin levels? (analysis pending) Annemieke Aartsma-Rus
PTC124/Ataluren dosing • Dosing not optimal • Research done • Optimized dosing
effect
• Bell shaped curve
concentration
• May be responders and non-responders • Extension studies re-initiated in USA and Europe • New placebo-controlled trial started in USA and Europe in 220 patients • Request for conditional approval in Europe Annemieke Aartsma-Rus
Stop codon readthrough summary
Annemieke Aartsma-Rus
Summary • Some therapeutic approaches are mutation specific: good diagnostics crucial • Much is known about Duchenne – mainly through research funded by patient organisations • No treatment available yet • Improved care has had huge impact on disease progression and quality of life
Annemieke Aartsma-Rus